Prasol Chemicals up 9.8% on strong Q1 FY27 results, Rs 500-600 cr capex plan

The investor presentation for the quarter ended June 30, 2026 (Q1 FY27) highlighted what management called the “highest ever quarterly performance on many key parameters” (page 6):

• Total revenue from operations of Rs 433.6 crores, up from Rs 319.6 crores in Q1 FY26 (page 7 and detailed P&L on page 10).
• EBITDA of Rs 90.3 crores versus Rs 40.6 crores a year ago (page 7 and 10).
• Profit after tax (PAT) of Rs 61.0 crores, compared with Rs 24.3 crores in Q1 FY26 (page 7 and 10).

Crucially for the market, the deck did not just show higher profits – it showed a step-change in profitability metrics:

• Gross margins rose to Rs 164.5 crores from Rs 95.8 crores, with gross margin percentage moving from 30.0% to 37.9% (page 8 and 10).
• EBITDA margin improved from 12.7% in Q1 FY26 to 20.8% in Q1 FY27 (page 7–8 and 10).
• PAT margin increased from 7.6% to 14.1% (page 8 and 10).

The presentation explicitly attributes part of this margin spike to temporary tailwinds. As noted on page 7 and highlighted again in the footnote to the Q1 charts on page 8, average selling prices benefited from “geopolitical-led supply chain issues” to the tune of Rs 25 crores in gross profit, along with a Rs 0.92 crores positive impact from foreign currency fluctuations. Management also cautions that they “expect normalisation in the coming quarters” (page 7).

Despite that caveat, the Street appears to be rewarding the combination of structural margin improvement and cyclical pricing support, especially given that this is the company’s maiden quarter as a listed entity.

The presentation (page 5) reminds investors that Prasol was successfully listed on 16 September 2026. That makes Q1 FY27 the first set of quarterly numbers investors can scrutinise after the IPO, and the deck goes beyond bare results to frame a narrative of improving operations and capital allocation.

Key elements that likely underpinned the stock move:

• The chairman’s message (page 6) calls Q1 FY27 “a strong start” with “healthy year-on-year revenue growth, driven by better realisations, higher volumes and an improving product mix,” and points to “sustainable improvement in utilizations at Mahad facility which has led to turnaround in profitability resulting in overall uptick in EBITDA margins.”
• The same message provides near-term guidance: Prasol “expect FY27 revenue of Rs 1,550–1,650 crores, with EBITDA of Rs. 240-250 crores excluding price fluctuations due to geopolitical-led supply chain issues and forex gains/ losses if any” (page 6). That explicit range gives investors a reference point for the rest of the year.

For a newly listed stock where expectations were being built ahead of the first board meeting, the confirmation of strong Q1 numbers and quantified FY27 guidance appears to have been a key catalyst.

While the company flags that Rs 25 crores of gross profit in Q1 came from higher average selling prices linked to supply chain disruptions (page 7–8), the deck also argues that margin gains are part of a longer structural trend.

On page 9, a chart titled “Structured Uptick in Margins Over the Years” shows:

• Gross margins rising from Rs 228.7 crores in FY24 to Rs 288.1 crores in FY25 and Rs 378.7 crores in FY26, with gross margin percentages of 26.1%, 28.5% and 30.7% respectively.
• EBITDA increasing from Rs 60.5 crores in FY24 to Rs 87.7 crores in FY25 and Rs 139.3 crores in FY26, with EBITDA margins of 6.9%, 8.7% and 11.3%.

The same slide links this progression to increased capacity under secondary and tertiary derivatives and the addition of new products such as ZDDP, IPH and PPS, while also acknowledging external shocks like Covid-19, the Russia–Ukraine war, supply chain challenges and the West Asia conflict (page 9).

Investors seem to be reading Q1 FY27’s 20.8% EBITDA margin (page 8 and 10) as an acceleration of that trend, aided but not solely driven by one-off pricing.

Beyond the quarter, the stock’s nearly 10% move also reflects how the company framed its next phase of growth.

On page 22, Prasol lays out a two-phase expansion plan:

• Phase I: Expansion in existing products with capex of about Rs. 250-300 Crores, largely through debottlenecking and process augmentation at Khopoli and Mahad, plus Rs. 50-60 crores in land and infrastructure development. The company expects this to be completed in multiple sub-phases over the next two years, with “revenue at peak utilization… expected to be Rs. 500-550 crores.”
• Phase II: Expansion for new R&D products with another Rs. 250-300 Crores of capex, including Rs. 50-60 crores in infrastructure. Products have been identified, site preparation and regulatory approvals are in progress, and capex spending is expected to begin in H2 FY28 (page 22).

The same slide states that Prasol aspires “to achieve Rs. 2,800 - 3,000 crores revenue over next 5 years,” with capex to be funded through internal accruals and debt (page 22). For a company that reported FY26 revenue from operations of Rs 1,232.6 crores (page 10 and 26), that target implies a substantial scale-up, which the market appears to be pricing in.

The Q1 deck also touches on operational and financial health that may be reassuring investors:

• The Mahad plant “had its best-ever quarterly production, and capacity utilisation improved” (page 7), important because historical data on page 26 shows that losses from Mahad reduced from Rs. 14.9 crores in FY24 to Rs. 3.9 crores in FY26.
• FY26 financial highlights (page 12 and 25) show revenue of Rs 1,232.6 crores, EBITDA of Rs 139.3 crores, PAT of Rs 83.1 crores, adjusted ROCE of 22.4% and net debt to equity of 0.19x.
• The utilisation of IPO proceeds table (page 29) shows that Rs 60.0 crores earmarked for repayment or prepayment of borrowings and Rs 16.4 crores for general corporate purposes – a total of Rs 76.4 crores – have already been deployed during Fiscal 2027.

These data points support the narrative that Prasol is entering its capex-heavy phase from a relatively comfortable balance sheet position.

The investor presentation does not provide quarter-on-quarter (sequential) comparisons for Q1 FY27 versus Q4 FY26, nor does it break out performance between domestic and export markets in numerical terms, though it notes that domestic sales “grew strongly” and exports grew year-on-year but were “held back” by West Asia conflict-related geopolitical tensions (page 7).

The filing also does not discuss order book visibility, specific customer wins, or detailed pricing trends beyond the quantified Rs 25 crores gross profit benefit from higher average selling prices and the Rs 0.92 crores forex impact (page 7–8).

Taken together, the Q1 FY27 deck gives investors three things at once: a sharp year-on-year jump in revenue and PAT, a visible and partly structural margin uplift, and a concrete capex and revenue roadmap for the next five years. Against the backdrop of a recent IPO and earlier speculative build-up ahead of results, the detailed confirmation of that story appears to be the main driver of Prasol Chemicals’ 9.8% rise to Rs 839 in Monday’s trade.

This article is for information only and is not investment advice.